ASCO 2015 Highlights

Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer.

Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer.

Olaparib maintenance may prolong progression-free survival in patients, regardless of the number of previous platinum-based chemotherapies.

Early intervention and supportive care for gastrointestinal and hepatic toxicities should be considered for patients receiving PARP inhibitors.

Analysis of high-grade serous ovarian cancers suggests that BRCA1/2-driven cancers have a more favorable mode of relapse than sporadic cancers.

Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established.

Once-weekly carfilzomib (Kyprolis) therapy at a higher dose significantly improved progression-free survival (PFS) and reduced the risk of disease progression or death compared with twice-weekly carfilzomib in patients with relapsed or refractory multiple myeloma. The overall safety profile for both regimens in the randomized phase 3 ARROW clinical trial were similar, said co-lead investigator María-Victoria Mateos, MD, PhD, Director, Myeloma Unit, University Hospital Salamanca-IBSAL, Spain, at the 2018 European Hematology Association Congress.